GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial

TAMPA, Florida, April 8, 2019 /CNW/ –GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology biotechnology company focused on innovative treatments based on

Read more

Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0

REHOVOT, Israel and NEW YORK, April 08, 2019 (GLOBE NEWSWIRE) — Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics

Read more

Interview: CEO Allen Davidoff of XORTX Therapeutics Inc.(OTCQB: XRTXF)

CEO Allen Davidoff of XORTX Therapeutics Inc., talks about their focus of developing therapies for kidney disease, diabetic nephropathy, and cardiovascular disease.

Read more

CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval

VANCOUVER, Washington, April 02, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company

Read more